Abbott Laboratories recently announced strong earnings despite facing challenges related to the shutdown of one of its infant formula-producing plants. The company reported revenue of $10.24 billion and earnings of $1.19 per share in Q4, surpassing street estimates. While ABT stock has shown a modest 6% increase this year, its growth potential seems limited.
Over the past three years, ABT stock has seen minimal movement, hovering around $115 compared to the S&P 500's 35% increase. Despite a 29% return in 2021, the stock underperformed in 2022 and 2023. This trend of lagging behind the S&P 500 has been observed across various sectors and companies.
